REPROGRAMMING MACROPHAGES IN HUMAN DISEASE

We develop unique macrophage-targeted small-molecule drugs

OUR APPROACH

Macrophage Pharma develops a new generation of powerful small-molecule immunotherapies which reprogram macrophage and dendritic cell function to combat disease based on our proprietary Esterase Sensitive Motif Technology™ (ESM™) platform.

ESM™ TECHNOLOGY

Our proprietary Esterase Sensitive Motif™ (ESM™) platform is a unique and validated technology platform that utilizes drug-amino acid ester conjugate for selectively delivering drugs into macrophages with exquisite specificity resulting in better pharmacology, efficacy and safety for best-in-class drugs against validated targets and biology as well as novel, first-in-class targets.

PIPELINE

Our lead programme, MPL-5821 is a first-in-class macrophage and dendritic cell targeted P38 MAPK inhibitor. MPL5821, is supported by a strong package of non-clinical immuno-oncology and early safety pharmacology data.

  • Latest News

  • Home

    Macrophage Pharma

    Macrophage Pharma is a biotechnology company focused on treating human disease by reprogramming macrophage function through transcriptional reprogramming and targeted drug-delivery leveraging our proprietary Esterase Sensitive Motif™ (ESM™) platform.

    We exploit our unique and validated ESM™ platform to develop and selective deliver drugs into macrophages and dendritic cells with exquisite specificity resulting in better pharmacology, efficacy and safety for best-in-class drugs against validated targets and biology as well as novel, first-in-class targets.

    Upcoming Events:

    After careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, Macrophage Pharma has...
    Read More